Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® in Adults with Moderate Atopic Dermatitis Biotech Investing
Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025 Pharmaceutical Investing
Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference Biotech Investing
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation Biotech Investing
Journey Medical Corporation Reports Combined Emrosi Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference Pharmaceutical Investing
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio Biotech Investing
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases Biotech Investing
